Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 365

1.

Distribution, silencing potential and evolutionary impact of promoter DNA methylation in the human genome.

Weber M, Hellmann I, Stadler MB, Ramos L, Pääbo S, Rebhan M, Schübeler D.

Nat Genet. 2007 Apr;39(4):457-66. Epub 2007 Mar 4.

PMID:
17334365
2.

Cell type-specific methylation of an intronic CpG island controls expression of the MCJ gene.

Strathdee G, Davies BR, Vass JK, Siddiqui N, Brown R.

Carcinogenesis. 2004 May;25(5):693-701. Epub 2004 Jan 16.

PMID:
14729589
4.

Aberrant de novo methylation of the p16INK4A CpG island is initiated post gene silencing in association with chromatin remodelling and mimics nucleosome positioning.

Hinshelwood RA, Melki JR, Huschtscha LI, Paul C, Song JZ, Stirzaker C, Reddel RR, Clark SJ.

Hum Mol Genet. 2009 Aug 15;18(16):3098-109. doi: 10.1093/hmg/ddp251. Epub 2009 May 28.

PMID:
19477956
5.

Chromatin inactivation precedes de novo DNA methylation during the progressive epigenetic silencing of the RASSF1A promoter.

Strunnikova M, Schagdarsurengin U, Kehlen A, Garbe JC, Stampfer MR, Dammann R.

Mol Cell Biol. 2005 May;25(10):3923-33.

6.

Predicting aberrant CpG island methylation.

Feltus FA, Lee EK, Costello JF, Plass C, Vertino PM.

Proc Natl Acad Sci U S A. 2003 Oct 14;100(21):12253-8. Epub 2003 Sep 30.

7.

A human CpG island randomly inserted into a plant genome is protected from methylation.

Meza TJ, Enerly E, Børu B, Larsen F, Mandal A, Aalen RB, Jakobsen KS.

Transgenic Res. 2002 Apr;11(2):133-42.

PMID:
12054347
8.
10.

Methyl-CpG binding proteins identify novel sites of epigenetic inactivation in human cancer.

Ballestar E, Paz MF, Valle L, Wei S, Fraga MF, Espada J, Cigudosa JC, Huang TH, Esteller M.

EMBO J. 2003 Dec 1;22(23):6335-45.

11.

Epigenetic basis for the transcriptional hyporesponsiveness of the human inducible nitric oxide synthase gene in vascular endothelial cells.

Chan GC, Fish JE, Mawji IA, Leung DD, Rachlis AC, Marsden PA.

J Immunol. 2005 Sep 15;175(6):3846-61.

12.

A profile of methyl-CpG binding domain protein occupancy of hypermethylated promoter CpG islands of tumor suppressor genes in human cancer.

Lopez-Serra L, Ballestar E, Fraga MF, Alaminos M, Setien F, Esteller M.

Cancer Res. 2006 Sep 1;66(17):8342-6.

14.

Monitoring methylation changes in cancer.

Beier V, Mund C, Hoheisel JD.

Adv Biochem Eng Biotechnol. 2007;104:1-11. Review.

PMID:
17290816
15.

Abnormal CpG island methylation occurs during in vitro differentiation of human embryonic stem cells.

Shen Y, Chow J, Wang Z, Fan G.

Hum Mol Genet. 2006 Sep 1;15(17):2623-35. Epub 2006 Jul 26.

PMID:
16870691
17.

[Profiles of DNA methylation in normal and cancer cells].

Weber M.

Med Sci (Paris). 2008 Aug-Sep;24(8-9):731-4. doi: 10.1051/medsci/20082489731. Review. French.

18.

A genome-wide screen for normally methylated human CpG islands that can identify novel imprinted genes.

Strichman-Almashanu LZ, Lee RS, Onyango PO, Perlman E, Flam F, Frieman MB, Feinberg AP.

Genome Res. 2002 Apr;12(4):543-54.

19.

Chromosome-wide and promoter-specific analyses identify sites of differential DNA methylation in normal and transformed human cells.

Weber M, Davies JJ, Wittig D, Oakeley EJ, Haase M, Lam WL, Schübeler D.

Nat Genet. 2005 Aug;37(8):853-62. Epub 2005 Jul 10.

PMID:
16007088
20.

Lineage-specific DNA methylation in T cells correlates with histone methylation and enhancer activity.

Schmidl C, Klug M, Boeld TJ, Andreesen R, Hoffmann P, Edinger M, Rehli M.

Genome Res. 2009 Jul;19(7):1165-74. doi: 10.1101/gr.091470.109. Epub 2009 Jun 3.

Supplemental Content

Support Center